Topical Osmoprotectant for the Management of Postrefractive Surgery-Induced Dry Eye Symptoms: A Randomised Controlled Double-Blind Trial

Table 1

Baseline demographical and ophthalmological examination data of patients randomised into FT and Op treatments.

	FT ()	Op ()	value
Age (years)	38.21 ± 11.52	33.00 ± 7.75	0.4425
Gender (as female %)	71.4%	54.5%	0.4108
OSDI (score)	14.48 ± 3.26	24.95 ± 5.99	0.1176
Schirmer 1 (mm/5 min)	21.22 ± 10.47	25.77 ± 10.85	0.0961
TBUT (sec)	8.18 ± 4.02	8.28 ± 3.89	0.9758
Fluorescein (score)	0.15 ± 0.36	0.32 ± 0.68	0.1644
Lissamine (score)	1.04 ± 0.61	0.82 ± 0.66	0.2342
BSCVA (LogMar)	0.002 ± 0.052	0.036 ± 0.072	0.109
Osmolarity (mOsm/L)	359.5 ± 9.52	383.3 ± 8.33	0.0781
Spherical equivalent (D)	−4.02 ± 2.8	−3.56 ± 1.7	0.5745
Contact lens users (%)	42.86%	44.44%	0.7219
Contact lens use (years)	9.2 ± 10.2	8.5 ± 4.2	0.6689

Values represent mean ± standard deviation. OSDI: ocular surface disease index; TBUT: tear film breakup time; BSCVA: best spectacle-corrected visual acuity.